Recipient, donor, and transplantation characteristics according to statin treatment at the time of transplantation
| . | All transplantations . | Statin treatment at allograft . | |||
|---|---|---|---|---|---|
| R−/D− . | R+/D− . | R−/D+ . | R+/D+ . | ||
| N | 567 | 464 | 16 | 75 | 12 |
| Recipient (patient) characteristics | |||||
| Median age, y (range) | 51 (20-74) | 50 (20-74) | 59 (51-66) | 57 (35-72) | 60 (40-70) |
| Female sex, n (%) | 273 (48) | 232 (50) | 3 (19) | 37 (49) | 1 (8) |
| Disease risk,* n (%) | |||||
| Standard | 249 (44) | 207 (45) | 5 (31) | 33 (44) | 4 (33) |
| High | 318 (56) | 257 (55) | 11 (69) | 42 (56) | 8 (67) |
| Donor characteristics | |||||
| Median age, y (range) | 50 (30-83) | 49 (30-78) | 55 (39-62) | 57 (34-80) | 58 (42-83) |
| Sex, female (%) | 284 (50) | 239 (52) | 7 (44) | 33 (44) | 5 (42) |
| Donor/recipient pairs | |||||
| Female/male, n (%) | 144 (25) | 116 (25) | 6 (38) | 17 (23) | 5 (42) |
| Other combinations, n (%) | 423 (75) | 348 (75) | 10 (63) | 58 (77) | 7 (58) |
| Transplantation characteristics | |||||
| Conditioning, n (%) | |||||
| Myeloablative | 372 (66) | 306 (66) | 8 (50) | 52 (69) | 6 (50) |
| Bu/Cy | 193 (34) | 158 (34) | 6 (38) | 24 (32) | 3 (25) |
| Cy/TBI | 103 (18) | 90 (19) | 1 (6) | 11 (15) | 1 (8) |
| Other | 76 (13) | 58 (13) | 1 (6) | 17 (23) | 2 (17) |
| Nonmyeloablative | 195 (34) | 158 (34) | 8 (50) | 23 (31) | 6 (50) |
| Stem cell source, n (%) | |||||
| PBSCs | 553 (97) | 451 (97) | 16 (100) | 74 (99) | 12 (100) |
| BM | 14 (3) | 13 (3) | 0 | 1 (1) | 0 |
| GVHD prophylaxis, n (%) | |||||
| Cyclosporin | 417 (74) | 340 (73) | 13 (81) | 54 (72) | 10 (84) |
| Tacrolimus | 150 (26) | 124 (27) | 3 (19) | 21 (28) | 2 (16) |
| . | All transplantations . | Statin treatment at allograft . | |||
|---|---|---|---|---|---|
| R−/D− . | R+/D− . | R−/D+ . | R+/D+ . | ||
| N | 567 | 464 | 16 | 75 | 12 |
| Recipient (patient) characteristics | |||||
| Median age, y (range) | 51 (20-74) | 50 (20-74) | 59 (51-66) | 57 (35-72) | 60 (40-70) |
| Female sex, n (%) | 273 (48) | 232 (50) | 3 (19) | 37 (49) | 1 (8) |
| Disease risk,* n (%) | |||||
| Standard | 249 (44) | 207 (45) | 5 (31) | 33 (44) | 4 (33) |
| High | 318 (56) | 257 (55) | 11 (69) | 42 (56) | 8 (67) |
| Donor characteristics | |||||
| Median age, y (range) | 50 (30-83) | 49 (30-78) | 55 (39-62) | 57 (34-80) | 58 (42-83) |
| Sex, female (%) | 284 (50) | 239 (52) | 7 (44) | 33 (44) | 5 (42) |
| Donor/recipient pairs | |||||
| Female/male, n (%) | 144 (25) | 116 (25) | 6 (38) | 17 (23) | 5 (42) |
| Other combinations, n (%) | 423 (75) | 348 (75) | 10 (63) | 58 (77) | 7 (58) |
| Transplantation characteristics | |||||
| Conditioning, n (%) | |||||
| Myeloablative | 372 (66) | 306 (66) | 8 (50) | 52 (69) | 6 (50) |
| Bu/Cy | 193 (34) | 158 (34) | 6 (38) | 24 (32) | 3 (25) |
| Cy/TBI | 103 (18) | 90 (19) | 1 (6) | 11 (15) | 1 (8) |
| Other | 76 (13) | 58 (13) | 1 (6) | 17 (23) | 2 (17) |
| Nonmyeloablative | 195 (34) | 158 (34) | 8 (50) | 23 (31) | 6 (50) |
| Stem cell source, n (%) | |||||
| PBSCs | 553 (97) | 451 (97) | 16 (100) | 74 (99) | 12 (100) |
| BM | 14 (3) | 13 (3) | 0 | 1 (1) | 0 |
| GVHD prophylaxis, n (%) | |||||
| Cyclosporin | 417 (74) | 340 (73) | 13 (81) | 54 (72) | 10 (84) |
| Tacrolimus | 150 (26) | 124 (27) | 3 (19) | 21 (28) | 2 (16) |
Bu indicates busulfan; Cy, cyclophosphamide; TBI, total body irradiation; BM, bone marrow; and MTX, methotrexate.
Standard disease risk refers to chronic myeloid leukemia in chronic phase, myelodysplastic syndromes without excess blasts, and leukemia and lymphoma in remission. High disease risk refers to all other hematologic malignancies.